Prognostic factors affecting survival in metastatic soft tissue XXXX : an analysis of 110 @entity1 .

@entity1 @entity242 @entity3012 @entity5 @entity1352 @entity1822
BACKGROUND: Data on treatment outcome and prognostic factors in @entity1 with metastatic soft tissue @entity242 (STS) are limited in the literature. METHODS: A total of 119 @entity1 with metastatic STS treated between June 2003 and December 2012 were analyzed for treatment outcome and prognostic factors. RESULTS: Median age was 37 years (range 2-72 years) with a male to female ratio of 1.5:1. Most common histologic subtypes were @entity1352 (36 %) and @entity1822 (16 %). Median @entity5 size was 12 cm (range 1.6-30 cm). Twenty-four (20 %) @entity1 were treated with multimodality therapy and 80 % @entity1 received systemic chemotherapy alone. At a median follow-up of 10 months (range 1-66 months), the 2-year EFS and @entity3012 were 10 and 19 %, respectively, with a median EFS and @entity3012 of 6 and 10 months, respectively. Univariate analysis identified albumin  <=4 g/dl (p = 0.001), histologic subtypes other than @entity1352 (p = 0.02), @entity5 (p = 0.03) and single modality treatment (p = 0.03) as factors predicting poor EFS; however, for @entity3012 , hemoglobin  <=10 g/dl (p = 0.02), @entity5 size >10 cm (p = 0.01) and single modality treatment (p = 0.04) were identified as poor prognostic factors. Multivariate analysis identified only serum albumin  <=4 g/dl (p = 0.002, HR 0.47, 95 % CI 0.29-0.75) associated with poor EFS; however, for @entity3012 , hemoglobin  <=10 g/dl (p = 0.009, HR 0.49, 95 % CI 0.29-0.83), @entity5 size >10 cm (p = 0.003, HR 2.11, 95 % CI 1.28-3.47) and single modality treatment (p = 0.01, HR 0.47, 95 % CI 0.25-0.86) emerged as poor prognostic factors. CONCLUSIONS: Serum albumin, @entity5 size, hemoglobin and treatment modality affect survival in metastatic STS.
